An interventional study of Percutaneous coronary intervention in ST Elevation Myocardial Infarction, sponsored by Tokai University. Enrolling by invitation at 1 site in Japan. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.
Sponsored by Tokai University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in ST Elevation Myocardial Infarction with a site in Japan — 1 open to participants now, 2 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Japan.
Among the 10 studies in ST Elevation Myocardial Infarction with a site in Japan, this one is the only one that started in 2022, is one of 5 with no phase, and was the 8th registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →1 of the 10 studies in ST Elevation Myocardial Infarction with a site in Japan is open now.
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 430 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 353 across the 8 interventional studies, 749 across the 2 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 9 most frequent:
Tokai University is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Tokai University has 2 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
1 of the studies in ST Elevation Myocardial Infarction with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in ST Elevation Myocardial Infarction with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test reducing procedure time of percutaneous coronary intervention (PCI) in ST elevation myocardial infarction by single catheter PCI (SC-PCI) method. The main question it aims to answer is:
Researchers will compare time from sheath insertion to first device activation between the SC-PCI method and the conventional method.
\<\<Background>>
Acute ST-segment elevation myocardial infarction is a disease of high acute-phase mortality rate, but the life can be saved by implementing emergency percutaneous coronary intervention (PCI). Its efficacy is higher than that of thrombolytic therapy. Moreover, shortening of total ischemia time reduces the mortality rate and can promote recovery of cardiac function. The total ischemia time can be classified into the time from onset to arrival at hospital and the time from arrival at hospital to recanalization of coronary artery (Door-to-balloon time), and shortening of time in all steps is recommended. Various methods, including the part of transportation to hospital and from arrival at hospital to treatment room, are proposed, but there is no effective method for shortening of procedure time for PCI.
Since the right and left dual-purpose universal guiding catheter can be inserted into both the left and right coronary arteries, the time for replacement of catheter can be shortened. Since IKARI Curve catheter is considered to be the most excellent catheter as the universal guiding catheter, it is considered useful for shortening of reperfusion time in myocardial infarction.
\<\<Objectives.>>
There are a lot of reports that decreased mortality and improvement of cardiac function are observed by shortening of the time from onset of acute myocardial infarction to recanalization. However, shortening of catheterization time, a part of the time, has not been examined. In 60 patients in a single-center retrospective study performed in Tokai University, the time from arterial puncture to reperfusion was shortened, and the time from arrival at hospital to reperfusion was also shortened. In 1275 patients in a multi-center retrospective study, moreover, the time from arterial puncture to reperfusion was significantly shortened by 4 minutes, and a significant decrease was also observed in the time from arrival at hospital to reperfusion. The Door-to-balloon time at this time was 68±46 minutes in the SC-PCI group and 76±51 minutes by the conventional method. Moreover, the time from insertion of sheath to balloon was 19±14 minutes in the SC-PCI group and 23±14 minutes by the conventional method. In addition, shortening of fluoroscopy time was also observed.
Based on this result, the information shall be collected from prospective multi-center randomized study and analyzed to verify that the right and left dual-purpose guiding catheter is useful for shortening of reperfusion time in myocardial infarction.
\<\<Methods.>>
Multi-center cooperative prospective interventional study, 2-group comparative study, and randomization \<Conventional method> If the patients are allocated to this group, the procedure shall be started with an angiographic catheter.
An angiographic catheter is a catheter classified into a special treatment material, "Angiographic Catheter (General Model) Request Code 738180000," and approved for insurance coverage. The catheters adopted by each institution shall be used.
Coronary angiography shall be performed using an angiographic catheter, and PCI shall be performed by replacing to a guiding catheter. There are methods in which a catheter for angiography on right and left sides is performed, a dual-purpose contrast catheter is used, and one contrast catheter and guiding catheter are used, but any method is acceptable if the procedure is started from an angiographic catheter.
\<SC-PCI method> When allocated to this group, the procedure shall be started with a guiding catheter of Ikari L Curve. As the Ikari L Curves approved for insurance coverage in Japan, 52 types exist by catalogue according to the difference in diameter and form, of 6 shafts of 5 companies (attached documents). Any of them shall be used. Thereafter, the right and left coronary angiography shall be performed with one right and left dual-purpose guiding catheter, and then PCI shall be performed.
Even if allocated to any group, Synergy stent shall be used when a stent is placed in coronary artery dilation.
A prospective randomization study shall be performed to reduce the bias. For the Sheath-to-First device activation time, a primary endpoint, a test of superiority shall be performed. For the Door-to-balloon time, a secondary endpoint, a test of non-inferiority shall be performed, and if the non-inferiority is demonstrated, a test of superiority shall also be performed.
The primary endpoint shall be analyzed by Intention-to-treat. The operators who can participate in this study shall take charge of any group, and who are the PCI operators who have used the Ikari L Curve guiding catheter on the right coronary artery in at least 5 patients and left coronary artery in at least 5 patients.
\<\<Number of Target Patients and Rationales for Setting>>
\<Number of target patients> 400 patients in total (200 patients for SC-PCI method, 200 patients for conventional method) \<Rationale for setting> In a multicenter retrospective study, the time from insertion of sheath to balloon (S2B) was 19±14 minutes in the SC-PCI group and 23±14 minutes for the conventional method. When testing at the level of significance of 0.05 and the power of 0.8 based on this value, the number of patients will become 388. Considering 3% dropout cases, registration of a total of 400 patients is planned.
A secondary endpoint, the D2B time was 68±46 minutes in the SC-PCI group and 76±51 minutes for the conventional method as a result of retrospective study. When testing at the level of significance of 0.05 and the power of 0.8 based on this value, the number of patients will become 1160. Therefore, the power is insufficient to show significance in the analysis of D2B time, and a non-inferiority test shall be performed. The margin of noninferiority is set at 1.3. If the D2B time by the conventional method is 76 minutes, the 1.3 times longer time is 98.8 minutes, and the difference is 22.8 minutes. In the treatment of myocardial infarction, the difference of 23 minutes or more is considered to be inferior from the standpoint of expert, and therefore it was set. Non-inferiority test shall be performed based on the 95% confidence interval (test of two-sided 5% or one-sided 2.5%) of the difference from mean value. If non-inferiority is shown, the test of superiority shall also be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Primary PCI is initiated with a universal guiding catheter (Ikari left). The guiding catheter is used to contrast the left and right coronary arteries and PCI is started directly. This method does not require a catheter exchange. It is Single Catheter PCI (SC-PCI) method.
Device: Percutaneous coronary intervention
Primary PCI is initiated with a diagnostic catheter. The catheter is used to contrast one of the coronary arteries. Then, the catheter is replaced with a contralateral side diagnostic catheter. Then, the catheter is replaced with a guiding catheter and PCI is started.
Device: Percutaneous coronary intervention
Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
Sheath-to-first device activation time
Time from insertion of sheath to reperfusion treatment apparatus (First device activation)
Time frame: the end of PCI
Door-to-balloon time
Time from arrival at hospital to reperfusion treatment apparatus (First device activation)
Time frame: the end of PCI
Total ischemia time
Time from the onset of myocardial infarction to achievement of TIMI 3 reperfusion
Time frame: the end of PCI
Fluoroscopy time and fluoroscopy dose
Radiation dose assessed as fluoroscopy time and dose
Time frame: the end of PCI
Amount of contrast medium
Dose of contrast medium used during PCI procedure
Time frame: the end of PCI
Number of catheters used
Total number of catheters used during the PCI procedure
Time frame: the end of PCI
Hospital expense
Total cost required for the total hospital stay
Time frame: 30 days
All-cause mortality and cardiovascular mortality at 30 days
All-cause mortality and cardiovascular mortality at 30 days
Time frame: At 30 days from the onset of STEMI
Hemorrhagic complication rate at 30 days
BARC 3 or 5 hemorrhagic complications
Time frame: At 30 days from the onset of STEMI
All-cause mortality and cardiovascular mortality at 1 year
All-cause mortality and cardiovascular mortality at 1 year
Time frame: 1 year after the randomization
Success rate of SC-PCI method
Success of SC-PCI method is defined as diagnostic angiography and PCI is performed using a single universal guiding catheter, Ikari left.
Time frame: the end of PCI
Plan to share: No — There are no plans to obtain IPD consent from patients.
Started Nov 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.
Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 25 months is below that.
Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Tokai University